{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:46:20Z","timestamp":1793828780701,"version":"4.6.1"},"reference-count":128,"publisher":"Keio Journal of Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Keio J. Med.","Keio j. med"],"published-print":{"date-parts":[[2022]]},"DOI":"10.2302\/kjm.2021-0004-ir","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T22:08:49Z","timestamp":1618006129000},"page":"1-12","source":"Crossref","is-referenced-by-count":25,"title":["HIF Inhibition Therapy in Ocular Diseases"],"prefix":"10.2302","volume":"71","author":[{"given":"Deokho","family":"Lee","sequence":"first","affiliation":[{"name":"Laboratory of Photobiology, Keio University School of              Medicine, Tokyo, Japan"},{"name":"Department of Ophthalmology, Keio University School of              Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Miwa","sequence":"additional","affiliation":[{"name":"Laboratory of Photobiology, Keio University School of              Medicine, Tokyo, Japan"},{"name":"Department of Ophthalmology, Keio University School of              Medicine, Tokyo, Japan"},{"name":"Animal Eye Care, Tokyo Animal Eye Clinic, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kunimi","sequence":"additional","affiliation":[{"name":"Laboratory of Photobiology, Keio University School of              Medicine, Tokyo, Japan"},{"name":"Department of Ophthalmology, Keio University School of              Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Ibuki","sequence":"additional","affiliation":[{"name":"Laboratory of Photobiology, Keio University School of              Medicine, Tokyo, Japan"},{"name":"Department of Ophthalmology, Keio University School of              Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiho","family":"Shoda","sequence":"additional","affiliation":[{"name":"Laboratory of Photobiology, Keio University School of              Medicine, Tokyo, Japan"},{"name":"Department of Ophthalmology, Keio University School of              Medicine, Tokyo, Japan"},{"name":"Department of Ophthalmology, Nihon University School of              Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Nakai","sequence":"additional","affiliation":[{"name":"Laboratory of Photobiology, Keio University School of              Medicine, Tokyo, Japan"},{"name":"Department of Ophthalmology, Keio University School of              Medicine, Tokyo, Japan"},{"name":"Department of Ophthalmology, Nihon University School of              Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Laboratory of Photobiology, Keio University School of              Medicine, Tokyo, Japan"},{"name":"Department of Ophthalmology, Keio University School of              Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1082","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Campochiaro PA: Ocular neovascularization. J Mol          Med 2013; 91: 311\u2013321. PMID:23329331,          DOI:10.1007\/s00109-013-0993-5","DOI":"10.1007\/s00109-013-0993-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ishibazawa A, Nagaoka T, Yokota H, Takahashi A,          Omae T, Song YS, Takahashi T, Yoshida A: Characteristics of retinal neovascularization in          proliferative diabetic retinopathy imaged by optical coherence tomography angiography.          Invest Ophthalmol Vis Sci 2016; 57: 6247\u20136255. PMID:27849310,          DOI:10.1167\/iovs.16-20210","DOI":"10.1167\/iovs.16-20210"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Rivera JC, Holm M, Austeng D, Morken TS, Zhou TE,          Beaudry-Richard A, Sierra EM, Dammann O, Chemtob S: Retinopathy of prematurity:          inflammation, choroidal degeneration, and novel promising therapeutic strategies. J          Neuroinflammation 2017; 14: 165. PMID:28830469,          DOI:10.1186\/s12974-017-0943-1","DOI":"10.1186\/s12974-017-0943-1"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Ambati J, Fowler BJ: Mechanisms of age-related          macular degeneration. Neuron 2012; 75: 26\u201339. PMID:22794258,          DOI:10.1016\/j.neuron.2012.06.018","DOI":"10.1016\/j.neuron.2012.06.018"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mansour SE, Browning DJ, Wong K, Flynn HW,          Bhavsar AR: The evolving treatment of diabetic retinopathy. Clin Ophthalmol 2020; 14:          653\u2013678. PMID:32184554, DOI:10.2147\/OPTH.S236637","DOI":"10.2147\/OPTH.S236637"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Patel RD, Blair MP, Shapiro MJ, Lichtenstein SJ:          Significant treatment failure with intravitreous bevacizumab for retinopathy of          prematurity. Arch Ophthalmol 2012; 130: 801\u2013802. PMID:22801851,          DOI:10.1001\/archophthalmol.2011.1802","DOI":"10.1001\/archophthalmol.2011.1802"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Stewart M: Extended duration vascular endothelial          growth factor inhibition in the eye: failures, successes, and future possibilities.          Pharmaceutics 2018; 10: 21. PMID:29382038,          DOI:10.3390\/pharmaceutics10010021","DOI":"10.3390\/pharmaceutics10010021"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Lima e Silva R, Shen J, Hackett SF, Kachi S,          Akiyama H, Kiuchi K, Yokoi K, Hatara MC, Lauer T, Aslam S, Gong YY, Xiao WH, Khu NH, Thut          C, Campochiaro PA: The SDF\u20101\/CXCR4 ligand\/receptor pair is an important contributor to          several types of ocular neovascularization. FASEB J 2007; 21: 3219\u20133230.          PMID:17522382, DOI:10.1096\/fj.06-7359com","DOI":"10.1096\/fj.06-7359com"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sengupta N, Afzal A, Caballero S, Chang KH, Shaw          LC, Pang JJ, Bond VC, Bhutto I, Baba T, Lutty GA, Grant MB: Paracrine modulation of CXCR4          by IGF-1 and VEGF: implications for choroidal neovascularization. Invest Ophthalmol Vis          Sci 2010; 51: 2697\u20132704. PMID:20007826, DOI:10.1167\/iovs.09-4137","DOI":"10.1167\/iovs.09-4137"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Hackett SF, Ozaki H, Strauss RW, Wahlin K, Suri          C, Maisonpierre P, Yancopoulos G, Campochiaro PA: Angiopoietin 2 expression in the retina:          upregulation during physiologic and pathologic neovascularization. J Cell Physiol 2000;          184: 275\u2013284. PMID:10911358,          DOI:10.1002\/1097-4652(200009)184:3&lt;275::AID-JCP1&gt;3.0.CO;2-7","DOI":"10.1002\/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima          T, Kurimoto M, Murakami T, Kimura T, Takagi H: Vitreous levels of angiopoietin 2 and          vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am          J Ophthalmol 2005; 139: 476\u2013481. PMID:15767056,          DOI:10.1016\/j.ajo.2004.10.004","DOI":"10.1016\/j.ajo.2004.10.004"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lee J, Park DY, Park DY, Park I, Chang W, Nakaoka          Y, Komuro I, Yoo OJ, Koh GY: Angiopoietin-1 suppresses choroidal neovascularization and          vascular leakage. Invest Ophthalmol Vis Sci 2014; 55: 2191\u20132199. PMID:24609620,          DOI:10.1167\/iovs.14-13897","DOI":"10.1167\/iovs.14-13897"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Nawaz MI, Van Raemdonck K, Mohammad G, Kangave D,          Van Damme J, Abu El-Asrar AM, Struyf S: Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in          retinal endothelial cells and are enhanced in diabetic retinopathy. Exp Eye Res 2013; 109:          67\u201376. PMID:23352833, DOI:10.1016\/j.exer.2013.01.008","DOI":"10.1016\/j.exer.2013.01.008"},{"key":"14","unstructured":"14. Abcouwer SF: Angiogenic factors and cytokines in          diabetic retinopathy. J Clin Cell Immunol 2013; (11, Suppl 1) 1\u201312.          PMID:24319628"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Lee WJ, Kang MH, Seong M, Cho HY: Comparison of          aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema          and macular oedema due to branch retinal vein occlusion. Br J Ophthalmol 2012; 96:          1426\u20131430. PMID:22930681, DOI:10.1136\/bjophthalmol-2012-301913","DOI":"10.1136\/bjophthalmol-2012-301913"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Fonollosa A, Garcia-Arumi J, Santos E, Macia C,          Fernandez P, Segura RM, Zapata MA, Rodriguez-Infante R, Boixadera A, Martinez-Castillo V:          Vitreous levels of interleukine-8 and monocyte chemoattractant protein-1 in macular oedema          with branch retinal vein occlusion. Eye (Lond) 2010; 24: 1284\u20131290. PMID:20111061,          DOI:10.1038\/eye.2009.340","DOI":"10.1038\/eye.2009.340"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Mitamura Y, Takeuchi S, Yamamoto S, Yamamoto T,          Tsukahara I, Matsuda A, Tagawa Y, Mizue Y, Nishihira J: Monocyte chemotactic protein-1          levels in the vitreous of patients with proliferative vitreoretinopathy. Jpn J Ophthalmol          2002; 46: 218\u2013221. PMID:12062231,          DOI:10.1016\/S0021-5155(01)00497-X","DOI":"10.1016\/S0021-5155(01)00497-X"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Schoenberger SD, Kim SJ, Sheng J, Rezaei KA,          Lalezary M, Cherney E: Increased prostaglandin E2 (PGE2) levels in proliferative diabetic          retinopathy, and correlation with VEGF and inflammatory cytokines. Invest Ophthalmol Vis          Sci 2012; 53: 5906\u20135911. PMID:22871833,          DOI:10.1167\/iovs.12-10410","DOI":"10.1167\/iovs.12-10410"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Mohamed Q, Gillies MC, Wong TY: Management of          diabetic retinopathy: a systematic review. JAMA 2007; 298: 902\u2013916. PMID:17712074,          DOI:10.1001\/jama.298.8.902","DOI":"10.1001\/jama.298.8.902"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Sim\u00f3 R, Hern\u00e1ndez C: Advances in the medical          treatment of diabetic retinopathy. Diabetes Care 2009; 32: 1556\u20131562. PMID:19638526,          DOI:10.2337\/dc09-0565","DOI":"10.2337\/dc09-0565"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Semenza GL: Hypoxia-inducible factor 1: master          regulator of O2 homeostasis. Curr Opin Genet Dev 1998; 8: 588\u2013594. PMID:9794818,          DOI:10.1016\/S0959-437X(98)80016-6","DOI":"10.1016\/S0959-437X(98)80016-6"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Semenza GL: Oxygen sensing, homeostasis, and          disease. N Engl J Med 2011; 365: 537\u2013547. PMID:21830968,          DOI:10.1056\/NEJMra1011165","DOI":"10.1056\/NEJMra1011165"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Wang GL, Jiang BH, Rue EA, Semenza GL:          Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by          cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510\u20135514. PMID:7539918,          DOI:10.1073\/pnas.92.12.5510","DOI":"10.1073\/pnas.92.12.5510"},{"key":"24","unstructured":"24.Kurihara T, Westenskow PD, Friedlander M:          Retinal Degenerative Diseases. eds Ash JD et al. 275\u2013281 Springer New          York."},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Arjamaa O, Nikinmaa M, Salminen A, Kaarniranta K:          Regulatory role of HIF-1\u03b1 in the pathogenesis of age-related macular degeneration (AMD).          Ageing Res Rev 2009; 8: 349\u2013358. PMID:19589398,          DOI:10.1016\/j.arr.2009.06.002","DOI":"10.1016\/j.arr.2009.06.002"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Goda N, Kanai M: Hypoxia-inducible factors and          their roles in energy metabolism. Int J Hematol 2012; 95: 457\u2013463. PMID:22535382,          DOI:10.1007\/s12185-012-1069-y","DOI":"10.1007\/s12185-012-1069-y"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Dengler VL, Galbraith MD, Espinosa JM:          Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol 2014;          49: 1\u201315. PMID:24099156, DOI:10.3109\/10409238.2013.838205","DOI":"10.3109\/10409238.2013.838205"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Semenza GL, Wang GL: A nuclear factor induced by          hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a          site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447\u20135454.          PMID:1448077, DOI:10.1128\/MCB.12.12.5447","DOI":"10.1128\/MCB.12.12.5447"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Firth JD, Ebert BL, Ratcliffe PJ: Hypoxic          regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and          cAMP response elements. J Biol Chem 1995; 270: 21021\u201321027. PMID:7673128,          DOI:10.1074\/jbc.270.36.21021","DOI":"10.1074\/jbc.270.36.21021"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. McIntosh BE, Hogenesch JB, Bradfield CA:          Mammalian Per-Arnt-Sim proteins in environmental adaptation. Annu Rev Physiol 2010; 72:          625\u2013645. PMID:20148691,          DOI:10.1146\/annurev-physiol-021909-135922","DOI":"10.1146\/annurev-physiol-021909-135922"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Hoffman E, Reyes H, Chu F, Sander F, Conley L,          Brooks B, Hankinson O: Cloning of a factor required for activity of the Ah (dioxin)          receptor. Science 1991; 252: 954\u2013958. PMID:1852076,          DOI:10.1126\/science.1852076","DOI":"10.1126\/science.1852076"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Tian H, McKnight SL, Russell DW: Endothelial PAS          domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial          cells. Genes Dev 1997; 11: 72\u201382. PMID:9000051,          DOI:10.1101\/gad.11.1.72","DOI":"10.1101\/gad.11.1.72"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Makino Y, Cao R, Svensson K, Bertilsson G, Asman          M, Tanaka H, Cao Y, Berkenstam A, Poellinger L: Inhibitory PAS domain protein is a          negative regulator of hypoxia-inducible gene expression. Nature 2001; 414: 550\u2013554.          PMID:11734856, DOI:10.1038\/35107085","DOI":"10.1038\/35107085"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Makino Y, Kanopka A, Wilson WJ, Tanaka H,          Poellinger L: Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant          of the hypoxia-inducible factor-3alpha locus. J Biol Chem 2002; 277: 32405\u201332408.          PMID:12119283, DOI:10.1074\/jbc.C200328200","DOI":"10.1074\/jbc.C200328200"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Ravenna L, Salvatori L, Russo MA: HIF3\u03b1: the          little we know. FEBS J 2016; 283: 993\u20131003. PMID:26507580,          DOI:10.1111\/febs.13572","DOI":"10.1111\/febs.13572"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36. Heikkil\u00e4 M, Pasanen A, Kivirikko KI, Myllyharju          J: Roles of the human hypoxia-inducible factor (HIF)-3\u03b1 variants in the hypoxia response.          Cell Mol Life Sci 2011; 68: 3885\u20133901. PMID:21479871,          DOI:10.1007\/s00018-011-0679-5","DOI":"10.1007\/s00018-011-0679-5"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37. Hara S, Hamada J, Kobayashi C, Kondo Y, Imura N:          Expression and characterization of hypoxia-inducible factor (HIF)-3\u03b1 in human kidney:          suppression of HIF-mediated gene expression by HIF-3\u03b1. Biochem Biophys Res Commun 2001;          287: 808\u2013813. PMID:11573933, DOI:10.1006\/bbrc.2001.5659","DOI":"10.1006\/bbrc.2001.5659"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw          ML, Bruick RK: FIH-1 is an asparaginyl hydroxylase enzyme that regulates the          transcriptional activity of hypoxia-inducible factor. Genes Dev 2002; 16: 1466\u20131471.          PMID:12080085, DOI:10.1101\/gad.991402","DOI":"10.1101\/gad.991402"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39. Jung F, Palmer LA, Zhou N, Johns RA: Hypoxic          regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac          myocytes. Circ Res 2000; 86: 319\u2013325. PMID:10679484,          DOI:10.1161\/01.RES.86.3.319","DOI":"10.1161\/01.RES.86.3.319"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Walford G, Loscalzo J: Nitric oxide in vascular          biology. J Thromb Haemost 2003; 1: 2112\u20132118. PMID:14521592,          DOI:10.1046\/j.1538-7836.2003.00345.x","DOI":"10.1046\/j.1538-7836.2003.00345.x"},{"key":"41","doi-asserted-by":"publisher","unstructured":"41. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E,          Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, Semenza GL: Cellular and          developmental control of O2 homeostasis by hypoxia-inducible factor 1alpha. Genes Dev          1998; 12: 149\u2013162. PMID:9436976, DOI:10.1101\/gad.12.2.149","DOI":"10.1101\/gad.12.2.149"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42. Zhang JZ, Behrooz A, Ismail-Beigi F: Regulation          of glucose transport by hypoxia. Am J Kidney Dis 1999; 34: 189\u2013202. PMID:10401038,          DOI:10.1016\/S0272-6386(99)70131-9","DOI":"10.1016\/S0272-6386(99)70131-9"},{"key":"43","doi-asserted-by":"publisher","unstructured":"43. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko          NC: HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen          consumption. Cell Metab 2006; 3: 187\u2013197. PMID:16517406,          DOI:10.1016\/j.cmet.2006.01.012","DOI":"10.1016\/j.cmet.2006.01.012"},{"key":"44","doi-asserted-by":"publisher","unstructured":"44. Kim J, Tchernyshyov I, Semenza GL, Dang CV:          HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required          for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177\u2013185. PMID:16517405,          DOI:10.1016\/j.cmet.2006.02.002","DOI":"10.1016\/j.cmet.2006.02.002"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45. Krock BL, Skuli N, Simon MC: Hypoxia-induced          angiogenesis: good and evil. Genes Cancer 2011; 2: 1117\u20131133. PMID:22866203,          DOI:10.1177\/1947601911423654","DOI":"10.1177\/1947601911423654"},{"key":"46","doi-asserted-by":"publisher","unstructured":"46. Fong GH: Mechanisms of adaptive angiogenesis to          tissue hypoxia. Angiogenesis 2008; 11: 121\u2013140. PMID:18327686,          DOI:10.1007\/s10456-008-9107-3","DOI":"10.1007\/s10456-008-9107-3"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper          OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC: Progenitor cell          trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med          2004; 10: 858\u2013864. PMID:15235597, DOI:10.1038\/nm1075","DOI":"10.1038\/nm1075"},{"key":"48","doi-asserted-by":"publisher","unstructured":"48. Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z,          Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA, Semenza GL: Cell type-specific regulation of          angiogenic growth factor gene expression and induction of angiogenesis in nonischemic          tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003; 93:          1074\u20131081. PMID:14576200, DOI:10.1161\/01.RES.0000102937.50486.1B","DOI":"10.1161\/01.RES.0000102937.50486.1B"},{"key":"49","doi-asserted-by":"publisher","unstructured":"49. Patel T, Kimura H, Weiss C, Semenza G, Hofmann L:          Constitutively active HIF-1\u03b1 improves perfusion and arterial remodeling in an endovascular          model of limb ischemia. Cardiovasc Res 2005; 68: 144\u2013154. PMID:15921668,          DOI:10.1016\/j.cardiores.2005.05.002","DOI":"10.1016\/j.cardiores.2005.05.002"},{"key":"50","doi-asserted-by":"publisher","unstructured":"50. Bosch-Marce M, Okuyama H, Wesley JB, Sarkar K,          Kimura H, Liu YV, Zhang H, Strazza M, Rey S, Savino L, Zhou YF, McDonald KR, Na Y,          Vandiver S, Rabi A, Shaked Y, Kerbel R, LaVallee T, Semenza GL: Effects of aging and          hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of          perfusion after limb ischemia. Circ Res 2007; 101: 1310\u20131318. PMID:17932327,          DOI:10.1161\/CIRCRESAHA.107.153346","DOI":"10.1161\/CIRCRESAHA.107.153346"},{"key":"51","doi-asserted-by":"publisher","unstructured":"51. Neely KA, Gardner TW: Ocular Neovascularization.          Am J Pathol 1998; 153: 665\u2013670. PMID:9736014,          DOI:10.1016\/S0002-9440(10)65607-6","DOI":"10.1016\/S0002-9440(10)65607-6"},{"key":"52","doi-asserted-by":"publisher","unstructured":"52. Ho L, van Leeuwen R, Witteman JC, van Duijn CM,          Uitterlinden AG, Hofman A, de Jong PT, Vingerling JR, Klaver CC: Reducing the genetic risk          of age-related macular degeneration with dietary antioxidants, zinc, and \u03c9-3 fatty acids:          the Rotterdam study. Arch Ophthalmol 2011; 129: 758\u2013766. PMID:21670343,          DOI:10.1001\/archophthalmol.2011.141","DOI":"10.1001\/archophthalmol.2011.141"},{"key":"53","doi-asserted-by":"publisher","unstructured":"53. Chew EY, Clemons TE, Agr\u00f3n E, Sperduto RD,          SanGiovanni JP, Kurinij N, Davis MD, Age-Related Eye Disease Study Research Group:          Long-term effects of vitamins C and E, \u03b2-carotene, and zinc on age-related macular          degeneration: AREDS report no. 35. Ophthalmology 2013; 120: 1604\u20131611.e4.          PMID:23582353, DOI:10.1016\/j.ophtha.2013.01.021","DOI":"10.1016\/j.ophtha.2013.01.021"},{"key":"54","doi-asserted-by":"publisher","unstructured":"54. Bhutto I, Lutty G: Understanding age-related          macular degeneration (AMD): Relationships between the photoreceptor\/retinal pigment          epithelium\/Bruch\u2019s membrane\/choriocapillaris complex. Mol Aspects Med 2012; 33: 295\u2013317.          PMID:22542780, DOI:10.1016\/j.mam.2012.04.005","DOI":"10.1016\/j.mam.2012.04.005"},{"key":"55","doi-asserted-by":"publisher","unstructured":"55. Lehmann GL, Benedicto I, Philp NJ,          Rodriguez-Boulan E: Plasma membrane protein polarity and trafficking in RPE cells: Past,          present and future. Exp Eye Res 2014; 126: 5\u201315. PMID:25152359,          DOI:10.1016\/j.exer.2014.04.021","DOI":"10.1016\/j.exer.2014.04.021"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Ford KM, Saint-Geniez M, Walshe T, Zahr A,          D\u2019Amore PA: Expression and role of VEGF in the adult retinal pigment epithelium. Invest          Ophthalmol Vis Sci 2011; 52: 9478\u20139487. PMID:22058334,          DOI:10.1167\/iovs.11-8353","DOI":"10.1167\/iovs.11-8353"},{"key":"57","doi-asserted-by":"publisher","unstructured":"57. Sparrow JR, Ueda K, Zhou J: Complement          dysregulation in AMD: RPE-Bruch\u2019s membrane-choroid. Mol Aspects Med 2012; 33: 436\u2013445.          PMID:22504022, DOI:10.1016\/j.mam.2012.03.007","DOI":"10.1016\/j.mam.2012.03.007"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Spilsbury K, Garrett KL, Shen WY, Constable IJ,          Rakoczy PE: Overexpression of vascular endothelial growth factor (VEGF) in the retinal          pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol          2000; 157: 135\u2013144. PMID:10880384,          DOI:10.1016\/S0002-9440(10)64525-7","DOI":"10.1016\/S0002-9440(10)64525-7"},{"key":"59","doi-asserted-by":"publisher","unstructured":"59. Blaauwgeers HG, Holtkamp GM, Rutten H, Witmer AN,          Koolwijk P, Partanen TA, Alitalo K, Kroon ME, Kijlstra A, van Hinsbergh VW, Schlingemann          RO: Polarized vascular endothelial growth factor secretion by human retinal pigment          epithelium and localization of vascular endothelial growth factor receptors on the inner          choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999; 155:          421\u2013428. PMID:10433935, DOI:10.1016\/S0002-9440(10)65138-3","DOI":"10.1016\/S0002-9440(10)65138-3"},{"key":"60","doi-asserted-by":"publisher","unstructured":"60. Ablonczy Z, Dahrouj M, Marneros AG: Progressive          dysfunction of the retinal pigment epithelium and retina due to increased VEGF\u2010A levels.          FASEB J 2014; 28: 2369\u20132379. PMID:24558195,          DOI:10.1096\/fj.13-248021","DOI":"10.1096\/fj.13-248021"},{"key":"61","doi-asserted-by":"publisher","unstructured":"61. Ibuki M, Shoda C, Miwa Y, Ishida A, Tsubota K,          Kurihara T: Lactoferrin has a therapeutic effect via HIF inhibition in a murine model of          choroidal neovascularization. Front Pharmacol 2020; 11: 174. PMID:32180725,          DOI:10.3389\/fphar.2020.00174","DOI":"10.3389\/fphar.2020.00174"},{"key":"62","doi-asserted-by":"publisher","unstructured":"62. Ibuki M, Lee D, Shinojima A, Miwa Y, Tsubota K,          Kurihara T: Rice bran and vitamin B6 suppress pathological neovascularization in a murine          model of age-related macular degeneration as novel HIF inhibitors. Int J Mol Sci 2020; 21:          8940. PMID:33255657, DOI:10.3390\/ijms21238940","DOI":"10.3390\/ijms21238940"},{"key":"63","doi-asserted-by":"publisher","unstructured":"63. Ibuki M, Shoda C, Miwa Y, Ishida A, Tsubota K,          Kurihara T: Therapeutic effect of Garcinia cambogia extract and hydroxycitric acid          inhibiting hypoxia-inducible factor in a murine model of age-related macular degeneration.          Int J Mol Sci 2019; 20: 5049. PMID:31614647,          DOI:10.3390\/ijms20205049","DOI":"10.3390\/ijms20205049"},{"key":"64","doi-asserted-by":"publisher","unstructured":"64. Lee CS, Choi EY, Lee SC, Koh HJ, Lee JH, Chung          JH: Resveratrol inhibits hypoxia-induced vascular endothelial growth factor expression and          pathological neovascularization. Yonsei Med J 2015; 56: 1678\u20131685. PMID:26446654,          DOI:10.3349\/ymj.2015.56.6.1678","DOI":"10.3349\/ymj.2015.56.6.1678"},{"key":"65","doi-asserted-by":"publisher","unstructured":"65. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD:          Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1\u03b1 and VEGF          expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther          2005; 4: 1465\u20131474. PMID:16227395,          DOI:10.1158\/1535-7163.MCT-05-0198","DOI":"10.1158\/1535-7163.MCT-05-0198"},{"key":"66","doi-asserted-by":"publisher","unstructured":"66. Park SY, Jeong KJ, Lee J, Yoon DS, Choi WS, Kim          YK, Han JW, Kim YM, Kim BK, Lee HY: Hypoxia enhances LPA-induced HIF-1\u03b1 and VEGF          expression: Their inhibition by resveratrol. Cancer Lett 2007; 258: 63\u201369.          PMID:17919812, DOI:10.1016\/j.canlet.2007.08.011","DOI":"10.1016\/j.canlet.2007.08.011"},{"key":"67","doi-asserted-by":"publisher","unstructured":"67. Cao Z, Fang J, Xia C, Shi X, Jiang BH:          trans-3,4,5\u2032-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular          endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res 2004;          10: 5253\u20135263. PMID:15297429, DOI:10.1158\/1078-0432.CCR-03-0588","DOI":"10.1158\/1078-0432.CCR-03-0588"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Song JH, Moon KY, Lee SC, Kim SS: Inhibition of          hypoxia-inducible factor-1\u03b1 and vascular endothelial growth factor by chrysin in a rat          model of choroidal neovascularization. Int J Mol Sci 2020; 21: 2842.          DOI:10.3390\/ijms21082842","DOI":"10.3390\/ijms21082842"},{"key":"69","doi-asserted-by":"publisher","unstructured":"69. Koo T, Park SW, Jo DH, Kim D, Kim JH, Cho HY, Kim          J, Kim JH, Kim JS: CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of          age-related macular degeneration. Nat Commun 2018; 9: 1855. PMID:29748595,          DOI:10.1038\/s41467-018-04175-y","DOI":"10.1038\/s41467-018-04175-y"},{"key":"70","doi-asserted-by":"publisher","unstructured":"70. Fetus and Newborn Committee, Canadian Paediatric          Society: Retinopathy of prematurity: A systematic review of the literature. Paediatr Child          Health 1998; 3: 173\u2013180. PMID:20401240, DOI:10.1093\/pch\/3.3.173","DOI":"10.1093\/pch\/3.3.173"},{"key":"71","doi-asserted-by":"publisher","unstructured":"71. Scott A, Fruttiger M: Oxygen-induced retinopathy:          a model for vascular pathology in the retina. Eye (Lond) 2010; 24: 416\u2013421.          PMID:20010791, DOI:10.1038\/eye.2009.306","DOI":"10.1038\/eye.2009.306"},{"key":"72","doi-asserted-by":"publisher","unstructured":"72. Hawkins BT, Davis TP: The blood-brain          barrier\/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173\u2013185.          PMID:15914466, DOI:10.1124\/pr.57.2.4","DOI":"10.1124\/pr.57.2.4"},{"key":"73","doi-asserted-by":"publisher","unstructured":"73. Yu X, Ji C, Shao A: Neurovascular unit          dysfunction and neurodegenerative disorders. Front Neurosci 2020; 14: 334.          PMID:32410936, DOI:10.3389\/fnins.2020.00334","DOI":"10.3389\/fnins.2020.00334"},{"key":"74","doi-asserted-by":"publisher","unstructured":"74. Rattner A, Williams J, Nathans J: Roles of HIFs          and VEGF in angiogenesis in the retina and brain. J Clin Invest 2019; 129: 3807\u20133820.          PMID:31403471, DOI:10.1172\/JCI126655","DOI":"10.1172\/JCI126655"},{"key":"75","doi-asserted-by":"publisher","unstructured":"75. Tomita Y, Ozawa N, Miwa Y, Ishida A, Ohta M,          Tsubota K, Kurihara T: Pemafibrate prevents retinal pathological neovascularization by          increasing FGF21 level in a murine oxygen-induced retinopathy model. Int J Mol Sci 2019;          20: 5878. PMID:31771164, DOI:10.3390\/ijms20235878","DOI":"10.3390\/ijms20235878"},{"key":"76","doi-asserted-by":"publisher","unstructured":"76. Miwa Y, Hoshino Y, Shoda C, Jiang X, Tsubota K,          Kurihara T: Pharmacological HIF inhibition prevents retinal neovascularization with          improved visual function in a murine oxygen-induced retinopathy model. Neurochem Int 2019;          128: 21\u201331. PMID:30872009, DOI:10.1016\/j.neuint.2019.03.008","DOI":"10.1016\/j.neuint.2019.03.008"},{"key":"77","doi-asserted-by":"publisher","unstructured":"77. Lee D, Miwa Y, Wu J, Shoda C, Jeong H, Kawagishi          H, Tsubota K, Kurihara T: A fairy chemical suppresses retinal angiogenesis as a HIF          inhibitor. Biomolecules 2020; 10: 1405. PMID:33020402,          DOI:10.3390\/biom10101405","DOI":"10.3390\/biom10101405"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Weidemann A, Krohne TU, Aguilar E, Kurihara T,          Takeda N, Dorrell MI, Simon MC, Haase VH, Friedlander M, Johnson RS: Astrocyte hypoxic          response is essential for pathological but not developmental angiogenesis of the retina.          Glia 2010; 58: 1177\u20131185. PMID:20544853, DOI:10.1002\/glia.20997","DOI":"10.1002\/glia.20997"},{"key":"79","doi-asserted-by":"publisher","unstructured":"79. Korovina I, Neuwirth A, Sprott D, Weber S, Pasha          SP, Gercken B, Breier G, El-Armouche A, Deussen A, Karl MO, Wielockx B, Chavakis T, Ameln          AK: Hematopoietic hypoxia\u2010inducible factor 2\u03b1 deficiency ameliorates pathological retinal          neovascularization via modulation of endothelial cell apoptosis. FASEB J 2019; 33:          1758\u20131770. PMID:30156910, DOI:10.1096\/fj.201800430R","DOI":"10.1096\/fj.201800430R"},{"key":"80","doi-asserted-by":"publisher","unstructured":"80. Shoda C, Miwa Y, Nimura K, Okamoto K, Yamagami S,          Tsubota K, Kurihara T: Hypoxia-inducible factor inhibitors derived from marine products          suppress a murine model of neovascular retinopathy. Nutrients 2020; 12: 1055.          PMID:32290307, DOI:10.3390\/nu12041055","DOI":"10.3390\/nu12041055"},{"key":"81","doi-asserted-by":"publisher","unstructured":"81. Kawagishi H: Are fairy chemicals a new family of          plant hormones? Proc Jpn Acad, Ser B, Phys Biol Sci 2019; 95: 29\u201338. PMID:30643094,          DOI:10.2183\/pjab.95.003","DOI":"10.2183\/pjab.95.003"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Mitchinson A: Fairy chemicals. Nature 2014; 505:          298\u2013298. DOI:10.1038\/505298a","DOI":"10.1038\/505298a"},{"key":"83","doi-asserted-by":"publisher","unstructured":"83. Yoshida T, Zhang H, Iwase T, Shen J, Semenza GL,          Campochiaro PA: Digoxin inhibits retinal ischemia\u2010induced HIF\u20101\u03b1 expression and ocular          neovascularization. FASEB J 2010; 24: 1759\u20131767. PMID:20065104,          DOI:10.1096\/fj.09-145664","DOI":"10.1096\/fj.09-145664"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR,          Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL: Digoxin and other cardiac          glycosides inhibit HIF-1 synthesis and block tumor growth. Proc Natl Acad Sci USA 2008;          105: 19579\u201319586. PMID:19020076, DOI:10.1073\/pnas.0809763105","DOI":"10.1073\/pnas.0809763105"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Usui-Ouchi A, Aguilar E, Murinello S, Prins M,          Gantner ML, Wright PE, Berlow RB, Friedlander M: An allosteric peptide inhibitor of HIF-1\u03b1          regulates hypoxia-induced retinal neovascularization. Proc Natl Acad Sci USA 2020; 117:          28297\u201328306. PMID:33106407, DOI:10.1073\/pnas.2017234117","DOI":"10.1073\/pnas.2017234117"},{"key":"86","doi-asserted-by":"publisher","unstructured":"86. Tomita Y, Lee D, Miwa Y, Jiang X, Ohta M, Tsubota          K, Kurihara T: Pemafibrate protects against retinal dysfunction in a murine model of          diabetic retinopathy. Int J Mol Sci 2020; 21: 6243. PMID:32872333,          DOI:10.3390\/ijms21176243","DOI":"10.3390\/ijms21176243"},{"key":"87","doi-asserted-by":"publisher","unstructured":"87. Araki M, Nakagawa Y, Oishi A, Han S, Wang Y,          Kumagai K, Ohno H, Mizunoe Y, Iwasaki H, Sekiya M, Matsuzaka T, Shimano H: The peroxisome          proliferator-activated receptor \u03b1 (PPAR\u03b1) agonist pemafibrate protects against          diet-induced obesity in mice. Int J Mol Sci 2018; 19: 2148. PMID:30041488,          DOI:10.3390\/ijms19072148","DOI":"10.3390\/ijms19072148"},{"key":"88","doi-asserted-by":"publisher","unstructured":"88. Fu Z, Gong Y, Liegl R, Wang Z, Liu CH, Meng SS,          Burnim SB, Saba NJ, Fredrick TW, Morss PC, Hellstrom A, Talukdar S, Smith LE: FGF21          administration suppresses retinal and choroidal neovascularization in mice. Cell Rep 2017;          18: 1606\u20131613. PMID:28199833, DOI:10.1016\/j.celrep.2017.01.014","DOI":"10.1016\/j.celrep.2017.01.014"},{"key":"89","doi-asserted-by":"publisher","unstructured":"89. Chen Y, Hu Y, Lin M, Jenkins AJ, Keech AC, Mott          R, Lyons TJ, Ma J: Therapeutic effects of PPAR\u03b1 agonists on diabetic retinopathy in type 1          diabetes models. Diabetes 2013; 62: 261\u2013272. PMID:23043158,          DOI:10.2337\/db11-0413","DOI":"10.2337\/db11-0413"},{"key":"90","doi-asserted-by":"publisher","unstructured":"90. Duh EJ, Sun JK, Stitt AW: Diabetic retinopathy:          current understanding, mechanisms, and treatment strategies. JCI Insight 2017; 2: e93751.          PMID:28724805, DOI:10.1172\/jci.insight.93751","DOI":"10.1172\/jci.insight.93751"},{"key":"91","doi-asserted-by":"publisher","unstructured":"91. Chatziralli IP: The role of glycemic control and          variability in diabetic retinopathy. Diabetes Ther 2018; 9: 431\u2013434. PMID:29190012,          DOI:10.1007\/s13300-017-0345-5","DOI":"10.1007\/s13300-017-0345-5"},{"key":"#cr-split#-92.1","doi-asserted-by":"crossref","unstructured":"92. Wang W, Lo A: Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci 2018","DOI":"10.3390\/ijms19061816"},{"key":"#cr-split#-92.2","doi-asserted-by":"crossref","unstructured":"19: 1816. PMID:29925789, DOI:10.3390\/ijms19061816","DOI":"10.3390\/ijms19061816"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Rodrigues M, Kashiwabuchi F, Deshpande M, Jee K,          Goldberg MF, Lutty G, Semenza GL, Montaner S, Sodhi A: Expression pattern of HIF-1\u03b1 and          VEGF supports circumferential application of scatter laser for proliferative sickle          retinopathy. Invest Ophthalmol Vis Sci 2016; 57: 6739\u20136746. PMID:27951596,          DOI:10.1167\/iovs.16-19513","DOI":"10.1167\/iovs.16-19513"},{"key":"94","doi-asserted-by":"publisher","unstructured":"94. Wang X, Wang G, Wang Y: Intravitreous vascular          endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative          diabetic retinopathy. Am J Ophthalmol 2009; 148: 883\u2013889. PMID:19837381,          DOI:10.1016\/j.ajo.2009.07.007","DOI":"10.1016\/j.ajo.2009.07.007"},{"key":"95","doi-asserted-by":"publisher","unstructured":"95. Yamada N, Horikawa Y, Oda N, Iizuka K, Shihara N,          Kishi S, Takeda J: Genetic variation in the hypoxia-inducible factor-1\u03b1 gene is associated          with type 2 diabetes in Japanese. J Clin Endocrinol Metab 2005; 90: 5841\u20135847.          PMID:16046581, DOI:10.1210\/jc.2005-0991","DOI":"10.1210\/jc.2005-0991"},{"key":"96","doi-asserted-by":"publisher","unstructured":"96. Ekberg NR, Eliasson S, Li YW, Zheng X,          Chatzidionysiou K, Falhammar H, Gu HF, Catrina SB: Protective effect of the HIF-1A          Pro582Ser polymorphism on severe diabetic retinopathy. J Diabetes Res 2019; 2019: 1\u20138.          PMID:31214621, DOI:10.1155\/2019\/2936962","DOI":"10.1155\/2019\/2936962"},{"key":"97","doi-asserted-by":"publisher","unstructured":"97. Olivares AM, Althoff K, Chen GF, Wu S, Morrisson          MA, DeAngelis MM, Haider N: Animal models of diabetic retinopathy. Curr Diab Rep 2017; 17:          93\u201393. PMID:28836097, DOI:10.1007\/s11892-017-0913-0","DOI":"10.1007\/s11892-017-0913-0"},{"key":"98","doi-asserted-by":"publisher","unstructured":"98. Mi X, Yuan TF, Zhong JX, Ding Y, So KF: Choosing          preclinical study models of diabetic retinopathy: key problems for consideration. Drug Des          Devel Ther 2014; 8: 2311\u20132319. PMID:25429204,          DOI:10.2147\/DDDT.S72797","DOI":"10.2147\/DDDT.S72797"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Feit-Leichman RA, Kinouchi R, Takeda M, Fan Z,          Mohr S, Kern TS, Chen DF: Vascular damage in a mouse model of diabetic retinopathy:          relation to neuronal and glial changes. Invest Ophthalmol Vis Sci 2005; 46: 4281\u20134287.          PMID:16249509, DOI:10.1167\/iovs.04-1361","DOI":"10.1167\/iovs.04-1361"},{"key":"100","doi-asserted-by":"publisher","unstructured":"100. Kumar S, Zhuo L: Longitudinal in vivo imaging of          retinal gliosis in a diabetic mouse model. Exp Eye Res 2010; 91: 530\u2013536.          PMID:20655908, DOI:10.1016\/j.exer.2010.07.010","DOI":"10.1016\/j.exer.2010.07.010"},{"key":"101","doi-asserted-by":"publisher","unstructured":"101. Wang Z, Yadav AS, Leskova W, Harris NR:          Attenuation of streptozotocin-induced microvascular changes in the mouse retina with the          endothelin receptor A antagonist atrasentan. Exp Eye Res 2010; 91: 670\u2013675.          PMID:20727883, DOI:10.1016\/j.exer.2010.08.008","DOI":"10.1016\/j.exer.2010.08.008"},{"key":"102","doi-asserted-by":"publisher","unstructured":"102. Wang Z, Yadav AS, Leskova W, Harris NR:          Inhibition of 20-HETE attenuates diabetes-induced decreases in retinal hemodynamics. Exp          Eye Res 2011; 93: 108\u2013113. PMID:21658386,          DOI:10.1016\/j.exer.2011.05.011","DOI":"10.1016\/j.exer.2011.05.011"},{"key":"103","doi-asserted-by":"publisher","unstructured":"103. Wright WS, Messina JE, Harris NR: Attenuation of          diabetes-induced retinal vasoconstriction by a thromboxane receptor antagonist. Exp Eye          Res 2009; 88: 106\u2013112. PMID:18996116,          DOI:10.1016\/j.exer.2008.10.008","DOI":"10.1016\/j.exer.2008.10.008"},{"key":"104","doi-asserted-by":"publisher","unstructured":"104. Kador PF, Takahashi Y, Wyman M, Ferris F:          Diabeteslike proliferative retinal changes in galactose-fed dogs. Arch Ophthalmol 1995;          113: 352\u2013354. PMID:7887849,          DOI:10.1001\/archopht.1995.01100030108031","DOI":"10.1001\/archopht.1995.01100030108031"},{"key":"105","doi-asserted-by":"publisher","unstructured":"105. Kowluru RA, Tang J, Kern TS, Effect of Long-Term          Administration of Antioxidants on the Development of Retinopathy: Abnormalities of retinal          metabolism in diabetes and experimental galactosemia. VII. Effect of long-term          administration of antioxidants on the development of retinopathy. Diabetes 2001; 50:          1938\u20131942. PMID:11473058, DOI:10.2337\/diabetes.50.8.1938","DOI":"10.2337\/diabetes.50.8.1938"},{"key":"106","doi-asserted-by":"publisher","unstructured":"106. Gaucher D, Chiappore JA, P\u00e2ques M, Simonutti M,          Boitard C, Sahel JA, Massin P, Picaud S: Microglial changes occur without neural cell          death in diabetic retinopathy. Vision Res 2007; 47: 612\u2013623. PMID:17267004,          DOI:10.1016\/j.visres.2006.11.017","DOI":"10.1016\/j.visres.2006.11.017"},{"key":"107","doi-asserted-by":"publisher","unstructured":"107. Sennello KA, Schulman RL, Prosek R, Siegel AM:          Systolic blood pressure in cats with diabetes mellitus. J Am Vet Med Assoc 2003; 223:          198\u2013201. PMID:12875445, DOI:10.2460\/javma.2003.223.198","DOI":"10.2460\/javma.2003.223.198"},{"key":"108","doi-asserted-by":"publisher","unstructured":"108. B\u00fcchi ER, Kurosawa A, Tso MO: Retinopathy in          diabetic hypertensive monkeys: a pathologic study. Graefes Arch Clin Exp Ophthalmol 1996;          234: 388\u2013398. PMID:8738706, DOI:10.1007\/BF00190716","DOI":"10.1007\/BF00190716"},{"key":"109","doi-asserted-by":"publisher","unstructured":"109. Ozaki H, Hayashi H, Vinores SA, Moromizato Y,          Campochiaro PA, Oshima K: Intravitreal sustained release of VEGF causes retinal          neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and          primates. Exp Eye Res 1997; 64: 505\u2013517. PMID:9227268,          DOI:10.1006\/exer.1996.0239","DOI":"10.1006\/exer.1996.0239"},{"key":"110","doi-asserted-by":"publisher","unstructured":"110. Vessey KA, Wilkinson-Berka JL, Fletcher EL:          Characterization of retinal function and glial cell response in a mouse model of          oxygen-induced retinopathy. J Comp Neurol 2011; 519: 506\u2013527. PMID:21192081,          DOI:10.1002\/cne.22530","DOI":"10.1002\/cne.22530"},{"key":"111","unstructured":"111. Wu KK, Huan Y: Streptozotocin-induced diabetic          models in mice and rats. Curr Protoc Pharmacol. Chapter 5 Unit 5.47,          (2008)."},{"key":"112","doi-asserted-by":"publisher","unstructured":"112. Mubarak A, Hodgson JM, Considine MJ, Croft KD,          Matthews VB: Supplementation of a high-fat diet with chlorogenic acid is associated with          insulin resistance and hepatic lipid accumulation in mice. J Agric Food Chem 2013; 61:          4371\u20134378. PMID:23586419, DOI:10.1021\/jf400920x","DOI":"10.1021\/jf400920x"},{"key":"113","doi-asserted-by":"publisher","unstructured":"113. Weinreb RN, Aung T, Medeiros FA: The          pathophysiology and treatment of glaucoma: a review. JAMA 2014; 311: 1901\u20131911.          PMID:24825645, DOI:10.1001\/jama.2014.3192","DOI":"10.1001\/jama.2014.3192"},{"key":"114","doi-asserted-by":"publisher","unstructured":"114. Rodrigues GB, Abe RY, Zangalli C, Sodre SL,          Donini FA, Costa DC, Leite A, Felix JP, Torigoe M, Diniz-Filho A, de Almeida HG:          Neovascular glaucoma: a review. Int J Retina Vitreous 2016; 2: 26. PMID:27895936,          DOI:10.1186\/s40942-016-0051-x","DOI":"10.1186\/s40942-016-0051-x"},{"key":"115","doi-asserted-by":"publisher","unstructured":"115. Shazly TA, Latina MA: Neovascular glaucoma:          etiology, diagnosis and prognosis. Semin Ophthalmol 2009; 24: 113\u2013121. PMID:19373696,          DOI:10.1080\/08820530902800801","DOI":"10.1080\/08820530902800801"},{"key":"116","doi-asserted-by":"publisher","unstructured":"116. Ergorul C, Ray A, Huang W, Wang DY, Ben Y,          Cantuti-Castelvetri I, Grosskreutz CL: Hypoxia inducible factor-1\u03b1 (HIF-1\u03b1) and some HIF-1          target genes are elevated in experimental glaucoma. J Mol Neurosci 2010; 42: 183\u2013191.          PMID:20237864, DOI:10.1007\/s12031-010-9343-z","DOI":"10.1007\/s12031-010-9343-z"},{"key":"117","doi-asserted-by":"publisher","unstructured":"117. Tezel G, Wax MB: Hypoxia-inducible factor 1alpha          in the glaucomatous retina and optic nerve head. Arch Ophthalmol 2004; 122: 1348\u20131356.          PMID:15364715, DOI:10.1001\/archopht.122.9.1348","DOI":"10.1001\/archopht.122.9.1348"},{"key":"118","doi-asserted-by":"publisher","unstructured":"118. Kunimi H, Miwa Y, Katada Y, Tsubota K, Kurihara          T: HIF inhibitor topotecan has a neuroprotective effect in a murine retinal          ischemia-reperfusion model. PeerJ 2019; 7: e7849\u2013e7849. PMID:31592359,          DOI:10.7717\/peerj.7849","DOI":"10.7717\/peerj.7849"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119. Kunimi H, Miwa Y, Inoue H, Tsubota K, Kurihara T:          A novel HIF inhibitor halofuginone prevents neurodegeneration in a murine model of retinal          ischemia\u2013reperfusion. Int J Mol Sci 2019; 20: 3171. PMID:31261724,          DOI:10.3390\/ijms20133171","DOI":"10.3390\/ijms20133171"},{"key":"120","doi-asserted-by":"publisher","unstructured":"120. Chang JH, Gabison EE, Kato T, Azar DT: Corneal          neovascularization. Curr Opin Ophthalmol 2001; 12: 242\u2013249. PMID:11507336,          DOI:10.1097\/00055735-200108000-00002","DOI":"10.1097\/00055735-200108000-00002"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121. Zheng Y, Kaye AE, Boker A, Stewart RK, Tey A,          Ahmad S, Willoughby CE, Bron AJ, Kaye SB: Marginal corneal vascular arcades. Invest          Ophthalmol Vis Sci 2013; 54: 7470\u20137477. PMID:24159088,          DOI:10.1167\/iovs.13-12614","DOI":"10.1167\/iovs.13-12614"},{"key":"122","unstructured":"122. Chen P, Yin H, Wang Y, Wang Y, Xie L: Inhibition          of VEGF expression and corneal neovascularization by shRNA targeting HIF-1\u03b1 in a mouse          model of closed eye contact lens wear. Mol Vis 2012; 18: 864\u2013873.          PMID:22511848"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123. Yang XM, Wang YS, Zhang J, Li Y, Xu JF, Zhu J,          Zhao W, Chu DK, Wiedemann P: Role of PI3K\/Akt and MEK\/ERK in mediating hypoxia-induced          expression of HIF-1\u03b1 and VEGF in laser-induced rat choroidal neovascularization. Invest          Ophthalmol Vis Sci 2009; 50: 1873\u20131879. PMID:19098317,          DOI:10.1167\/iovs.08-2591","DOI":"10.1167\/iovs.08-2591"},{"key":"124","doi-asserted-by":"publisher","unstructured":"124. Fu YC, Xin ZM: Inhibited corneal          neovascularization in rabbits following corneal alkali burn by double-target interference          for VEGF and HIF-1\u03b1. Biosci Rep 2019; 39: BSR20180552. PMID:30355648,          DOI:10.1042\/BSR20180552","DOI":"10.1042\/BSR20180552"},{"key":"125","doi-asserted-by":"publisher","unstructured":"125.Baker H, Sidorowicz A, Sehgal SN, V\u00e9zina C:          Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation.          J Antibiot (Tokyo) 1978; 31 : 539\u2013545. PMID:28309,          DOI:10.7164\/antibiotics.31.539.","DOI":"10.7164\/antibiotics.31.539"},{"key":"126","doi-asserted-by":"publisher","unstructured":"126. Kwon YS, Hong HS, Kim JC, Shin JS, Son Y:          Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest          Ophthalmol Vis Sci 2005; 46: 454\u2013460. PMID:15671269,          DOI:10.1167\/iovs.04-0753","DOI":"10.1167\/iovs.04-0753"},{"key":"127","doi-asserted-by":"publisher","unstructured":"127. Zhang Y, Zhang T, Ma X, Zou J: Subconjunctival          injection of antagomir-21 alleviates corneal neovascularization in a mouse model of          alkali-burned cornea. Oncotarget 2017; 8: 11797\u201311808. PMID:28052006,          DOI:10.18632\/oncotarget.14370","DOI":"10.18632\/oncotarget.14370"}],"container-title":["The Keio Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kjm\/71\/1\/71_2021-0004-IR\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:50:40Z","timestamp":1715233840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kjm\/71\/1\/71_2021-0004-IR\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2302\/kjm.2021-0004-ir","relation":{},"ISSN":["0022-9717","1880-1293"],"issn-type":[{"value":"0022-9717","type":"print"},{"value":"1880-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"2021-0004-IR"}}